DTIL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Precision BioSciences Inc (DTIL) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company has a promising FDA-approved clinical trial for Duchenne muscular dystrophy, its financial performance is weak, with significant revenue decline and negative EPS. Additionally, insider selling and bearish technical indicators suggest caution. Given the lack of strong trading signals and the absence of recent congress trading data, it is better to hold off on investing in DTIL for now.
The MACD is slightly positive, indicating mild bullish momentum, but the RSI is neutral at 53.974, offering no clear signal. The moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading near its pivot level of 3.834, with resistance at 4.056 and support at 3.612. Overall, the technical indicators suggest a bearish trend.
The FDA approval to initiate a Phase 1/2 clinical trial for PBGENE-DMD, targeting Duchenne muscular dystrophy, is a significant positive catalyst. The program has the potential to address a large unmet medical need, with initial data expected by the end of 2026.
Insider selling has increased by 711.58% over the last month, indicating a lack of confidence from company insiders. The company's financials show a significant revenue drop of -97.74% YoY in Q3 2025, and the stock is underperforming with a bearish technical setup.
In Q3 2025, the company's revenue dropped significantly by -97.74% YoY to $13,000. Net income improved to -$21,772,000 (up 32.55% YoY), but EPS declined to -1.84, down -18.22% YoY. Gross margin remained at 100%, but the overall financial performance is weak.
No recent analyst rating or price target changes are available for DTIL. Wall Street sentiment is neutral, with no significant trading trends from hedge funds.
